The future of drug discovery.
Latest Developments
Critical Outcome Technologies Inc. and DDP Therapeutics announce promising preliminary test results for Small Cell Lung Cancer molecules.
jan. 24th, 2007
Critical Outcome Technologies Inc. has received promising preliminary results regarding in vitro drug resistance in lung cancer cell lines for the first 3 Small Cell Lung Cancer lead molecules.
Official Press Release
Critical Outcome Technologies Inc. announces $1 M private placement.
jan. 17th, 2007
Critical Outcome Technologies is pleased to announce that the Company has raised, by way of a non-brokered private placement, $1 M through the issuance of 2,000,000 Units at a price of $0.50 per Unit.
Official Press Release
Dr Wayne R Danter, President and CSO of Critical Outcome Technologies, Inc. to present at the 5th annual BioPartnering North America Conference in Vancouver, Canada, February 4-6, 2007.
jan. 2nd, 2007
Dr W.R. Danter and Mr. Gene Kelly (CFO) of Critical Outcome Technologies will be attending BioPartnering 2007 North America and will be pleased to meet with prospective partners. Call 1-519-858-5157 to arrange your meeting now.
Dr Danter will also be presenting an overview of the computational process (CHEMSAS®) for the targeted discovery, optimization and selection of COTI’s portfolio of highly optimized lead compounds specifically engineered for the oral treatment of acute Multiple Sclerosis. The first 4 of these novel compounds are nearing the end of synthesis and are expected to enter testing in the animal model of acute allergic encephalitis in February 2007.
Critical Outcome Technologies Inc. reports second quarter financial results.
jan. 2nd, 2007
Official Press Release
Critical Outcome Technologies Inc. announces the final selection of its library of orally available lead compounds for the treatment of acute Multiple Sclerosis.
nov. 7th, 2006
London, Ontario - (CCNMatthews - Nov. 7, 2006) - Critical Outcome Technologies Inc. (TSX-V: COT), a computational drug discovery and pre-clinical drug development company, has completed the discovery, optimization and final selection of its library of lead compounds for the oral treatment of acute Multiple Sclerosis.
Official Press Release
TSXV approves proposed Qualifying Transaction.
oct. 30th, 2006
Critical Outcome Technologies Inc. is pleased to announce that the TSXV has approved the proposed amalgamation with Aviator Petroleum Corporation.
The COTI Common Shares are to commence trading on the Exchange under the symbol “COT” on October 30, 2006.
Official Press Release
TSXV conditionally approves proposed Qualifying Transaction.
aug. 14th, 2006
Critical Outcome Technologies is pleased to announce that the TSXV has conditionally approved the proposed amalgamation with Aviator Petroleum Corporation.
Official Press Release
Critical Outcome Technologies is pleased to welcome Dr. Rainer Engelhardt to its Board of Directors.
june. 30th, 2006
[Dr. Engelhardt's Bio]
Critical Outcome Technologies welcomes Mr. Michael Barr as Director of Marketing and Business Development.
may. 17th, 2006
[Mr. Barr's Bio]
Critical Outcome Technologies appoints Dr. Henrick Hansen to its Scientific Advisory Board.
may. 17th, 2006
[Dr. Hansen's Bio]
Critical Outcome Technologies, Inc and Aviator Petroleum Corp. a capital pool company (CPC) on the Toronto Venture Exchange (AVC.P) announce a letter of intent regarding a proposed amalgamation.
may. 4th, 2006
[download document]
Critical Outcome Technologies' lead compounds COTI2-MO5, COTI4-MO5 and COTI219-M05 significantly reduce both tumor number and tumor size in a nude mouse model of Human Small Cell Lung Cancer (SHP-77) with no significant observed toxicity.
april. 10th, 2006
[read more]
Dr. Wayne Danter to present at Salford Systems Data Mining Conference in San Diego California.
feb. 28th, 2006
[read more]
Mr. Bruno Maruzzo joins COTI's Board of Directors.
jan. 26th, 2006
[Mr. Maruzzo's Bio]
Dr. Brigitte LeBreton appointed as Scientific Advisor.
jan. 16th, 2006
[Dr. LeBreton's Bio]
Critical Outcome Technologies to attend the 4th annual BioPartnering North America Conference in Vancouver, Canada from February 5-7, 2006 inclusive.
jan. 4th, 2006
[read more]
Mr. John Drake appointed CEO and member of the Advisory Board for Critical Outcome Technologies.
dec. 12th, 2005
[Mr. Drake's Bio]